IL17A and rheumatoid arthritis: Various IL-17 blocking agents have been developed and are currently being tested in RA (summarized in Table 2), psoriasis, ankylosing spondylitis, and inflammatory bowel diseases, including Secukinumab, Ixekizumab, and Brodalumab [87].